Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.33 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944971 | 0.79 | MAN2B1 (0.32) | MAN2B1IDUA | |
| SCHEMBL4174353 | 0.75 | — | — | |
| SCHEMBL7329550 | 0.74 | CTSD (0.32) | CTSDMEN1KMT2A | |
| SCHEMBL7329555 | 0.74 | CTSD (0.32) | CTSDMEN1KMT2A | |
| SCHEMBL7329562 | 0.74 | CTSD (0.32) | CTSDMEN1KMT2A | |
| SCHEMBL4963985 | 0.74 | CTSD (0.32) | CTSDMEN1KMT2A | |
| SCHEMBL14003990 | 0.74 | CTSD (0.36) | CTSD | |
| SCHEMBL30500436 | 0.72 | CTSD (0.34) | CTSDMEN1KMT2A | |
| SCHEMBL17815474 | 0.72 | MAN2B1 (0.31) | MAN2B1 | |
| SCHEMBL29360124 | 0.71 | MEN1 (0.35) | CTSDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975091-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2021-04-13 | — | — | US | disclosed |
| EP-3150581-B1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2020-04-15 | — | — | EP | disclosed |
| US-20200055868-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2020-02-20 | — | — | US | disclosed |
| EP-3228616-B1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-10421762-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20180327418-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2018-11-15 | — | — | US | disclosed |
| US-10059720-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2018-08-28 | — | — | US | disclosed |
| US-10005762-B2 | Pyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170362209-A1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3228616-A1 | PYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-3150581-A1 | PYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-0681568-B1 | PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND BETA-LACTAM INTERMEDIATES THEREFOR | UNIV NEW YORK STATE RES FOUND (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-0690856-B1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | UNIV NEW YORK STATE RES FOUND (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6218553-B1 | METALLIZATION BY REACTING A BACCATIN III DERIVATIVE WITH A METAL ALKYLDISILAZIDE | THE STATE UNIVERSITY OF NEW YORK AT STONY BROOK | 2001-04-17 | — | — | US | disclosed |
| US-6187916-B1 | Process for the preparation of taxane derivatives and β-lactam intermediates therefor | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2001-02-13 | — | — | US | disclosed |
| US-5705508-A | FORMING TAXOL DERIVATIVES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-01-06 | — | — | US | disclosed |
| US-5599820-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0690856-A4 | — | UNIV NEW YORK (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0690856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005762-B2 | Pyridine derivatives | LAP3, PREP, DNPEP | CTSD 517/4885MAN2B1 953/4885IDUA 33/4885 |
| US-20200055868-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | CTSD 484/4885MAN2B1 1008/4885IDUA 41/4885 |
| US-10975091-B2 | Pyridine derivative | LAP3, PREP, DNPEP | CTSD 484/4885MAN2B1 1008/4885IDUA 41/4885 |
| US-20180327418-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | CTSD 484/4885MAN2B1 1008/4885IDUA 41/4885 |
| US-10059720-B2 | Pyridine derivative | LAP3, PREP, DNPEP | CTSD 484/4885MAN2B1 1008/4885IDUA 41/4885 |
| US-20170362209-A1 | PYRIDINE DERIVATIVES | LAP3, PREP, DNPEP | CTSD 517/4885MAN2B1 953/4885IDUA 33/4885 |
| US-10421762-B2 | Pyridine derivative | LAP3, PREP, DNPEP | CTSD 484/4885MAN2B1 1008/4885IDUA 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.